| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 06/13/2002 | WO2001075019A3 A novel polypeptide - human ataxia - telangiectasia mutein 11 andthe polynucleotide encoding said polypeptide |
| 06/13/2002 | WO2001072721A3 Synergistic methods and compositions for treating cancer |
| 06/13/2002 | WO2001072277A3 Immunotherapeutic methods and compositions |
| 06/13/2002 | WO2001070233A3 Apoptosis inhibiting composition comprising a 15-keto-prostaglandin or derivative thereof |
| 06/13/2002 | WO2001059103A3 Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression |
| 06/13/2002 | WO2001044300A3 Brain specific binding members |
| 06/13/2002 | WO2001042461A3 Apoptin-associating protein |
| 06/13/2002 | WO2001037819A3 Use of indirubine derivatives for making medicines |
| 06/13/2002 | US20020072631 2-amino-2-alkyl-3 hexenoic and hexynoic acid derivatives useful as nitric oxide synthase inhibitors |
| 06/13/2002 | US20020072630 Therapy |
| 06/13/2002 | US20020072624 As antiestrogenic and anti-proliferative agent |
| 06/13/2002 | US20020072609 Process for preparing arylacetylaminothiazoles |
| 06/13/2002 | US20020072592 Nucleotide sequences which code anticarcinogenic agent for use in the treatment mammary gland cancer |
| 06/13/2002 | US20020072540 For therapy, prophylaxis and diagnosis of respiratory distress syndrome or other pulmonary diseases that are associated with deficiency of lung surfactant |
| 06/13/2002 | US20020072534 20- Hete antagonists and agonists |
| 06/13/2002 | US20020072528 Are immunomodulators and induce cytokine biosynthesis, including interferon and/or tumor biosynthesis, necrosis factor, and inhibit T-helper-type 2 immune response; useful for therapy of viral and neoplastic diseases |
| 06/13/2002 | US20020072526 Orally active salts with tyrosine kinase activity |
| 06/13/2002 | US20020072523 For therapy of inflammatory and immune diseases |
| 06/13/2002 | US20020072518 Bicyclic alphavbeta3 antagonists |
| 06/13/2002 | US20020072517 Substituted cyclic amine metalloprotease inhibitors |
| 06/13/2002 | US20020072510 3-nitrogen-6,7-dioxygen steroids and uses related thereto |
| 06/13/2002 | US20020072507 Combretastatin A-4 phosphate prodrug mono-and di-organic amine salts, mono--and di-amino acid salts, and mono-and di-amino acid ester salts |
| 06/13/2002 | US20020072504 Method and reagents for genetic immunization |
| 06/13/2002 | US20020072500 3-(carboxy(hydroxy)alkylaminocarbonylmethylaminocarbonyl), 5-(tetrahydropyrimidin-2-yl-amino)phenol for example |
| 06/13/2002 | US20020072494 Angiogenesis inhibitor, K1-5 (protease-activated kringles 1-5) genetically engineered so it can be secreted from cells in which it is expressed; contains a secretory signal peptide and a pre-activation peptide derived from plasminogen |
| 06/13/2002 | US20020072491 Homology to members of the myosin light chain kinase subfamily |
| 06/13/2002 | US20020072488 Amino acid sequences of human transporter peptides and proteins that are related to the sugar transporter subfamily; identifying modulators of the transporter peptides |
| 06/13/2002 | US20020072485 Administering prior to the impairment of glucose and/or oxygen to the brain an NMDA receptor subunit (NR2B) selective NMDA antagonist to inhibit neuronal damage (ischemia) |
| 06/13/2002 | US20020072119 Preventing tumor growth; obtain cells, transform with expression vector, monitor cells for reduction in cell proliferation |
| 06/13/2002 | US20020072115 Pancreatic islet cell growth factors |
| 06/13/2002 | US20020072107 Human osteoclast derived cathepsin |
| 06/13/2002 | US20020072090 Hr-1 receptor |
| 06/13/2002 | US20020071878 Anti proliferative preparations |
| 06/13/2002 | US20020071843 Targeted therapeutic agents |
| 06/13/2002 | US20020071835 Bacterial strain, processed plant extracts, compositions containing same, processes for their preparation and their therapeutic and industrial applications |
| 06/13/2002 | US20020071832 Use of mutant herpes viruses and anticancer agents in the treatment of cancer |
| 06/13/2002 | US20020071822 Polymer comprising a backbone comprising ester, thioester, or amide linkages, and wherein the backbone comprises one or more groups that will yield a biologically active compound upon hydrolysis of the polymer. |
| 06/13/2002 | US20020071808 Method for imaging malignant tumors using carbon 13 with MRI |
| 06/13/2002 | US20020071807 Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
| 06/13/2002 | CA2436984A1 Urea substituted imidazoquinoline ethers |
| 06/13/2002 | CA2436983A1 Sulfonamido ether substituted imidazoquinolines |
| 06/13/2002 | CA2436916A1 Use of pyrazolo[4,3-d]pyrimidines |
| 06/13/2002 | CA2436870A1 Substituted anthranilic acids |
| 06/13/2002 | CA2436856A1 Immunomodulatory constructs and their uses |
| 06/13/2002 | CA2436732A1 Protein modification and maintenance molecules |
| 06/13/2002 | CA2436666A1 Use of zwitterionic polysaccharides for the specific modulation of immune processes |
| 06/13/2002 | CA2436601A1 Perturbed membrane-binding compounds |
| 06/13/2002 | CA2435467A1 Benzyl (idene)-lactams and their use as 5ht1-receptor ligands |
| 06/13/2002 | CA2431861A1 Method of detecting and treating tuberous sclerosis complex associated disorders |
| 06/13/2002 | CA2431203A1 Polypeptide sequences of drug metabolizing enzymes and polynucleotide sequences coding therefor |
| 06/13/2002 | CA2431202A1 Human sprouty-4 polypeptide |
| 06/13/2002 | CA2431187A1 Macroheterocylic compounds useful as kinase inhibitors |
| 06/13/2002 | CA2431171A1 Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof |
| 06/13/2002 | CA2431166A1 Indazolyl-substituted pyrroline compounds as kinase inhibitors |
| 06/13/2002 | CA2431151A1 Heterocyclic ether substituted imidazoquinolines |
| 06/13/2002 | CA2431040A1 Substituted imidazopyridines |
| 06/13/2002 | CA2430998A1 Expression of keratin genes 8 and 18 for treating tumours, in particular a mammary carcinoma |
| 06/13/2002 | CA2430993A1 G-protein coupled receptors |
| 06/13/2002 | CA2430966A1 Anilinopyrimidine derivatives as jnk pathway inhibitors and compositions and methods related thereto |
| 06/13/2002 | CA2430844A1 Aryl ether substituted imidazoquinolines |
| 06/13/2002 | CA2430769A1 Novel estrogen receptor ligands and methods iii |
| 06/13/2002 | CA2430685A1 A substance or composition for the treatment of cancer |
| 06/13/2002 | CA2430624A1 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 06/13/2002 | CA2430621A1 Vaccine composition containing transforming growth factor alpha |
| 06/13/2002 | CA2430558A1 Proteins and nucleic acids encoding same |
| 06/13/2002 | CA2430466A1 Klainetin and derivatives thereof, method for their production and the use of the same |
| 06/13/2002 | CA2430412A1 Substituted 2-anilino-benzimidazoles and the use thereof as nhe-inhibitors |
| 06/13/2002 | CA2430379A1 Endogenous retroviruses up-regulated in prostate cancer |
| 06/13/2002 | CA2430376A1 Semicarbazides and their uses as cyclin dependent kinase inhibitors |
| 06/13/2002 | CA2430355A1 Tetralone derivatives as antitumor agents |
| 06/13/2002 | CA2430206A1 Screening method for identifying compounds that selectively induce interferon alpha |
| 06/13/2002 | CA2429769A1 Methods of treatment involving human mda-7 |
| 06/13/2002 | CA2429728A1 Tyrosine kinase inhibitors |
| 06/13/2002 | CA2429641A1 Kinases and phosphatases |
| 06/13/2002 | CA2428390A1 Enzymes |
| 06/13/2002 | CA2428382A1 Intestinal proteins |
| 06/13/2002 | CA2428208A1 Lipid-associated molecules |
| 06/13/2002 | CA2427615A1 Aspergillus ochraceus 11 alpha hydroxylase and oxidoreductase |
| 06/12/2002 | EP1213351A2 Nucleic acid enzymes acquiring an activity for cleaving a target RNA by recognising another molecule |
| 06/12/2002 | EP1213300A1 Novel human androgen receptor variants |
| 06/12/2002 | EP1213289A1 N-benzenesulfonyl L-proline compounds as bradykinin antagonists |
| 06/12/2002 | EP1213288A1 Propanoic acid derivatives that inhibit the binding of integrins to their receptors |
| 06/12/2002 | EP1213032A1 Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| 06/12/2002 | EP1213028A1 Hm1.24 antigen expression potentiators |
| 06/12/2002 | EP1213023A1 Kit comprising reovirus |
| 06/12/2002 | EP1212621A1 Screening for agents modulating tgf-beta cell signalling |
| 06/12/2002 | EP1212455A1 Antisense modulation of telomeric repeat binding factor 1 expression |
| 06/12/2002 | EP1212436A2 Protein phosphatase and kinase proteins |
| 06/12/2002 | EP1212433A2 Protein phosphatases and diagnosis and treatment of phosphatase-related disorders |
| 06/12/2002 | EP1212428A1 Cell-specific and/or tumor-specific promoter retargeting of herpes gamma 34.5 gene expression |
| 06/12/2002 | EP1212422A2 Human ctla-4 antibodies and their uses |
| 06/12/2002 | EP1212421A1 Gas1 polypeptides |
| 06/12/2002 | EP1212419A2 Polycyclic aromatic hydrocarbon induced molecules |
| 06/12/2002 | EP1212417A2 Interleukin-1-receptor associated kinase-3 (irak3) |
| 06/12/2002 | EP1212416A2 Nucleic acid based modulators of gene expression |
| 06/12/2002 | EP1212413A1 A transmembrane trap for isolating membrane bound proteins |
| 06/12/2002 | EP1212408A2 Bryostatins, bryopyrans and polyketides: compositions and methods |
| 06/12/2002 | EP1212407A1 Immunoglobulin superfamily polynucleotides, polypeptides, and antibodies |
| 06/12/2002 | EP1212405A2 Use of cytokines, cells, and mitogens to inhibit graft versus host disease |
| 06/12/2002 | EP1212404A2 Isolation of muscle-derived stem cells and uses therefore |